^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
07/22/2014
Excerpt:
Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma. Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
Secondary therapy:
Chemotherapy; bendamustine
Source:
Published date:
11/01/2013
Excerpt:
...in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma.
Secondary therapy:
Chemotherapy; bendamustine
Source:
Title:
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Published date:
11/26/2020
Excerpt:
Obinutuzumab or rituximab in combination with CHOP or bendamustine should be used if complete remission and long PFS are the therapeutic goals [I, B]. If there is evidence of more aggressive clinical course, obinutuzumab/rituximab-CHOP should be applied.
Secondary therapy:
CHOP; bendamustine
DOI:
10.1016/j.annonc.2020.11.008
Source:
Excerpt:
Follicular Lymphoma: First-line therapy…Preferred regimens…Bendamustine + obinutuzumab or rituximab...
Secondary therapy:
cyclophosphamide + prednisone; bendamustine
Source:
Excerpt:
Follicular Lymphoma: First-line consolidation or Extended dosing…Preferred regimens following chemoimmunotherapy…Obinutuzumab maintenance (1000 mg every 8 weeks for 12 doses)
